PEGFILGRASTIM BIOSIMILARS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Regional Analysis

To learn more about this report, Request sample copy

North America dominates the global pegfilgrastim biosimilars market with an estimated market share of 41.3% in 2024. The U.S. market alone accounts for over 40% share due to huge demand for biosimilars from healthcare facilities as well as favorable reimbursement policies promoting their usage over reference biologics. Furthermore, presence of large regional pharmaceutical companies with established manufacturing and distribution networks aids product accessibility. While Canada also contributes significantly, future growth may be tempered by pricing pressures from government payers.

Asia Pacific region has emerged as the fastest growing market for pegfilgrastim biosimilars globally over the past few years. Countries such as China, India, South Korea and Japan are witnessing increasing adoption due to growing cancer patient pools as well as massive investments by both domestic and multinational companies to expand local manufacturing capabilities. This ensures reliable and affordable supply to meet domestic treatment needs. The Chinese market exhibit double digit expansion annually with government impetus on developing a strong biosimilars industry under the “Made in China 2025” program.